scispace - formally typeset
H

Horst Feldmann

Researcher at Ludwig Maximilian University of Munich

Publications -  102
Citations -  8365

Horst Feldmann is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Gene & Transfer RNA. The author has an hindex of 30, co-authored 100 publications receiving 8086 citations.

Papers
More filters
Journal Article

[Isolation and identification of PACE-binding protein rpn4--a new transcription activator, participating in regulation of 26S proteosome and other genes].

TL;DR: A new upstream activating sequence (UAS) 5'-GGTGGCAAA-3' was detected in the promoters of 27 out of the 33 proteasomal genes and of several genes related to the ubiquitin-proteasomal system of Saccharomices cerevisiae.
Journal ArticleDOI

Different Patterns of Transposable Elements in the Vicinity of tRNA Genes in Yeast: a Possible Clue to Transcriptional Modulation

TL;DR: The authors' analyses revealed that complex patterns exist in which different types of elements (Ty, delta, sigma, and tau) are involved and in several there are alleles of which one contains a particular element and the other lacks it.
Journal ArticleDOI

3-D conformal radiotherapy of localized prostate cancer: a subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effects.

TL;DR: There is no evidence that prostate cancer patients presenting with endoscopic verified pathological findings in the rectal mucosa at diagnosis are at an increased risk to develop rectal side effects when treated with 3D-CRT of the prostatic region.
Journal ArticleDOI

Conserved and non-conserved features among the yeast Ty elements.

TL;DR: A comparison of the best-conserved amino acid homologies for these putative proteins of Ty elements, transposable elements from other organisms and several retroviral proviruses are included to confirm their close structural resemblance.
Journal ArticleDOI

Biochemische Kontrolle nach konformaler, dreidimensionaler Strahlentherapie des Prostatakarzinoms

TL;DR: Eine 3-D-konformale Strahlentherapie in Verbindung mit einer kurzzeitigen neoadjuvanten Hormontherapie erhielten, zeigen trotz höherer initialer PSA-Werte ein vergleichbares 3-Jahres biochemisch rezidivfreies Überleben.